- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diagnosis of Intestinal Parasites
- Drug Monitoring, Antidepressants, With Confirmation, Urine and Serum
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- No FAQs found
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
TSHTest code(s) 899
Question 1. What is TSH and how is it measured?
Thyroid stimulating hormone (TSH) is one of the most important hormones currently used to diagnose thyroid abnormalities. This glycoprotein is secreted by the pituitary and stimulates release of thyroxine (T4) and triiodothyronine (T3) from the thyroid gland. TSH release from the pituitary is controlled by thyrotropin releasing hormone (TRH) stimulation and negative feedback from free T3 and free T4.
We currently test TSH using an ultrasensitive 3rd generation chemiluminescent assay (sensitivity = 0.01 mIU/L). A high TSH concentration typically suggests hypothyroidism, whereas a low concentration suggests a hyperthyroid state.
Question 2. Does the time of day matter when sampling for TSH testing?
Yes. TSH concentration follows a diurnal rhythm. Typically, the peak occurs around midnight and the nadir (~50% of the peak value) around mid-day. Population-based reference intervals are generally obtained from subjects tested in the daytime, closer to the trough than to the peak. So, when evaluating a patient’s serial TSH concentrations, differences in sample collection time should be considered.
Question 3. How variable is TSH?
TSH has moderate intraindividual variability and even more marked interindividual variability. The interindividual coefficient of variation is about 32%; consequently there is a wide population-based reference interval for TSH. Since the intraindividual variation is considerably less, comparing a specific patient’s current TSH level with any past level may be more illuminating than comparing the patient’s current TSH level to the reference interval. A difference of 0.7 mIU/L or greater is considered significant when evaluating a patient’s serial TSH values.1
Question 4. My patient’s free T4 and TSH results do not seem to correlate. Which should I believe?
That depends on the clinical situation. There are multiple things that can give the appearance of discrepant results even though they are not truly discrepant. For example, an elevation or drop in TSH with a normal free T4 may be one of the first signs of subclinical disease. In subclinical hypothyroidism, the elevated TSH is allowing the body to “compensate,” keeping the free T4 concentration normal. Many, but not all, of these patients will progress to frank disease if left untreated, so such concentrations may need to be monitored.
In general, TSH appears to be the more sensitive indicator of thyroid hormone status. However, it may take days to weeks for TSH concentrations to reestablish a steady state following changes in thyroid dosing (or when a noncompliant patient takes “extra” medication just before being seen by the doctor). In these circumstances the free T4 may be the more reliable indicator of the current thyroid hormone status.
In another example, a patient with successfully treated Graves hyperthyroidism may appear euthyroid by all indications other than a suppressed TSH level. In most cases, allowing up to 6-8 weeks for TSH to stabilize after a significant change in thyroid hormone status will be sufficient, although some patients with Graves disease may have suppressed TSH for months even after treatment has restored euthyroidism.
Question 5. My patient’s TSH is much higher than I expected. Could there be some interference causing this?
Antibody interference may be the cause. Some patients develop heterophilic antibodies such as human anti-mouse antibodies (HAMA). HAMA can interfere with many standard immunoassays, causing either an artificially high (or low) result. If you suspect your patient has a heterophilic antibody, the test can be repeated using either a different method or specific blocking agents. Such agents are used in the TSH with HAMA Treatment test (test code 19537).
Other factors can also cause a higher than expected TSH result. Hypothyroidism and patient compliance withmedication are common causes.
Question 6. I’ve heard different recommendations for TSH reference intervals. What should I use as a “normal” value?
The TSH reference interval is still controversial. One reason is that TSH measurement is dependent on the method used. Different concentrations can be obtained from different assays. Therefore, when monitoring a patient, we recommend using the same assay from the same laboratory.
Another reason for varying reference intervals is the variation in study results and expert opinion. A review of data from NHANES III suggests that the upper limit of the reference interval is close to 4 mIU/L.2 The National Academy of Clinical Biochemists has suggested a much lower cutoff of 2.5 mIU/L.3 In 2012, the American Association of Clinical Endocrinologists (AACE) and the American Thyroid Association (ATA) suggested using the reference interval established by any given laboratory that is using a third generation TSH assay. If this is not available, the next option would be to use the NHANES III range of 0.45-4.12 mIU/L.4
Most clinical laboratories have not lowered the upper cutoff for TSH based on observations that “22 to 28 million more Americans would be diagnosed with hypothyroidism without any clinical or therapeutic benefit from this diagnosis.”5 Surveys of academic clinical endocrinologists have shown that many physicians may monitor patients more frequently once the TSH rises above the 2.5 to 3.0 mIU/L cutoff, but few will treat until the TSH is significantly higher (eg, 10 mIU/L or more) or unless other significant cofactors (eg, antithyroid antibodies, low free T4) are present.
Different TSH clinical cutoffs are used for pregnant women. These cutoffs are based on clinical studies showing adverse health effects of maternal hypothyroidism for both mother and infant. The ATA released guidelines in 2011 that specify lower cutoffs for TSH during pregnancy.6 If a lab does not have its own trimester-specific TSH reference intervals, then the ATA suggests using a TSH reference interval of 0.1–2.5 mIU/L during the first trimester, 0.2–3.0 mIU/L during the second trimester, and 0.3–3.0 mIU/L during the third trimester. Not all those who have a TSH above the trimester-specific cutoff need treatment, but they should all be evaluated further (eg, TPO antibody testing) and monitored more closely.
Low TSH values (below the laboratory’s reference interval) do not always indicate hyperthyroidism and a need to treat. Low values might indicate a need for further evaluation, especially when symptoms of hyperthyroidism are present.
- Browning MC, Ford RP, Callaghan SJ, et al. Intra- and interindividual biological variation of five analytes used in assessing thyroid function: implications for necessary standards of performance and the interpretation of results. Clin Chem. 1986;32:962-966.
- Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
- Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005;90:5483-5488.
- Garber J, Cobin R, Gharib H, et al.Clinical Practice Guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endo Pract. 2012;18:989-1028.
- Fatourechi V.Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin Proc. 2009;84:65-71.
- Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-1125.